BioNTech Forecasts Q2 Loss of €2.09/Share, Revenue Down 39.5%; Names New CEO
BNTX sits 16% above its 52-week low of $79.52.
Summary
BioNTech is forecast to report a Q2 2026 loss of €2.09 per share on revenue of about €157.7M, a 39.5% year-over-year decline. The company also named Guido Oelkers as CEO, effective February 1, 2027, succeeding co-founder Ugur Sahin, who is leaving to start a new venture. The search for a new Chief Medical Officer is underway. This follows a May restructuring that cut 25% of the workforce and a $1B buyback program launched in June. The sharp revenue drop and leadership transition signal ongoing challenges as the company pivots toward its oncology pipeline.
At the time of this announcement, BNTX was trading at $91.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.9B. The 52-week trading range was $79.52 to $124.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.